Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $151.64, a high estimate of ...

'Mad Money' host Jim Cramer weighs in on stock including: Anavex Life Sciences, Sarepta Therapeutics, Viking Therapeutics, ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...

Santhera Pharmaceuticals has started launch preparations for its DMD drug Agamree (vamorolone) in the UK, after a ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Hold rating on Kymera Therapeutics (KYMR – Research ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.

The rising incidence of cancer is boosting the demand for advanced diagnostic tools, such as exosome-based diagnostics, which provide non-invasive and accurate detection methods. In addition to ...

Swings in the bond market recently sent the yield on the 10-year Treasury above 4.80% and its highest level since 2023. The ...

Roche has exercised its option to license a novel capsid from Dyno Therapeutics for use in a gene therapy program for an ...

The OIG report points to gaps in documentation and decision-making transparency, particularly in the case of Aduhelm, where FDA records indicated only 13 meetings with Biogen, but congressional ...